Qualifying target candidates – Pure MHC can compare a partner’s putative targets against its proprietary database of normal tissues to determine potential for cross-reactivity.
Existing Target Validation and Tissue Distribution – Partners that have already selected antigens for immune targeting can enlist Pure MHC to validate that a target is detected in the appropriate tissues and to determine a quantitative measurement of the target’s immunogenicity.
Full Length HLA – In addition to soluble HLA, Pure MHC also has developed Full Length constructs and transfectants for Class I, Class II, and non-classical HLA applications.
Companion Diagnostics – Cell surface biomarkers and mAb to these biomarkers can be utilized to develop companion diagnostics to assess the effectiveness of antigen/epitope delivery and antigen/epitope presentation.
Regulatory Compliance Support – Companies with a validated target in a formulated vaccine have enlisted Pure MHC to provide companion diagnostics to demonstrate target expression on vaccinated cells and lot-to-lot QC testing for regulatory compliance purposes.
Other Custom Services – In addition to soluble HLA, Pure MHC also has developed Full Length constructs and transfectants for Class I, Class II, and non-classical HLA applications.
Pure MHC, LLC
Administrative Office
7500 Rialto Blvd.
Building Two, Suite 260
Austin, TX 78735
Research Laboratory
655 Research Parkway
Suite 556
Oklahoma City, OK 73104